| 0 (0%) | 09-27 14:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.21 | 1-year : | 4.64 |
| Resists | First : | 3.6 | Second : | 3.98 |
| Pivot price | 3.19  |
|||
| Supports | First : | 3 | Second : | 2.49 |
| MAs | MA(5) : | 3.21  |
MA(20) : | 3.21 |
| MA(100) : | 3.54 |
MA(250) : | 8.37 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.7 |
D(3) : | 49.2 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 18.88 | Low : | 2.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RCKT ] has closed below upper band by 28.0%. Bollinger Bands are 81.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.26 - 3.28 | 3.28 - 3.29 |
| Low: | 3.1 - 3.12 | 3.12 - 3.13 |
| Close: | 3.23 - 3.26 | 3.26 - 3.29 |
Sat, 27 Sep 2025
What analysts say about RCKT stock - Currency Fluctuation Impact & Learn to Trade with Real-Time Feedback - Early Times
Tue, 23 Sep 2025
Sovran Advisors LLC Sells 127,063 Shares of Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Mon, 22 Sep 2025
Cantor Fitzgerald Reiterates Overweight Rating on Rocket Pharmaceuticals (RCKT) - StreetInsider
Thu, 28 Aug 2025
Rocket Pharmaceuticals Stock (RCKT) Opinions on FDA Clinical Hold Lift | RCKT Stock News - Quiver Quantitative
Thu, 21 Aug 2025
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely? - simplywall.st
Thu, 21 Aug 2025
Bank of America Upgrades Rocket Pharma Stock (RCKT) After FDA Lifts Clinical Hold on Danon Disease Trial - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 108 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 89.9 (%) |
| Shares Short | 15,490 (K) |
| Shares Short P.Month | 11,230 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.1 % |
| Return on Equity (ttm) | -69.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -204 (M) |
| Levered Free Cash Flow | -101 (M) |
| PE Ratio | -1.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|